HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT
HRMY 12.03.2024

About Gravity Analytica
Recent News
- 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
- 01.13.2025 - Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts
- 12.18.2024 - HARMONY BIOSCIENCES TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Recent Filings
A webcast of the fireside chat will be available on the investor page of Harmony's website athttps://ir.harmonybiosciences.com/.
About Harmony BiosciencesHarmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visitwww.harmonybiosciences.com.
Harmony Biosciences Investor Contact:
Harmony Biosciences Media Contact:
View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-participate-in-oppenheimer-movers-in-rare-disease-summit-302320185.html
SOURCE